STOCKHOLM--(BUSINESS WIRE)--Regulatory News: Moberg Pharma AB (STO:MOB) today announced that Moberg Pharma and Colep – a leading global player in the consumer goods packaging and contract manufacturing industries – entered a Development Agreement for MOB-015 – a novel topical formulation of terbinafine for onychomycosis (nail fungus).
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.